retatrutide type 2 diabetes phase 2 results 2024 2025 🚨 Today, retatrutide, the GIP/GLP-1/glucagon triple agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent obesity and diabetes. 📊 Mean body weight change at 80 weeks: ⬇️ Efficacy and Safety of Retatrutide

Retatrutide, with its triple action on GLP-1, GIP, and glucagon receptors, is the most advanced example yet

What happens if someone is undernourished after years of eating a poor diet on these appetite-suppressing drugs and then gets to the point where they can no longer obtain them

Experts stress caution in extrapolating these findings to humans and call for clinical trials to clarify how weight loss drugs affect muscle size and strength

[DOI] [PMC free article] [PubMed] [Google Scholar] 165.Jakicic J.M., Rogers R.J., Church T.S

Tirzepatide microdosing example Strategy A: Titration with smaller increments (compounded version) Tirzepatide come in the form of prefilled pens in fixed, single-use doses (e.g., 2.5 mg, 5 mg, etc.)